12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Deals

Santaris, Bristol-Myers deal

Santaris and Bristol-Myers partnered to discover and develop RNA-targeted therapies for undisclosed indications using the biotech's Locked Nucleic Acid (LNA) technology. Santaris will...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >